Organisation paid for research Program year 2025 Source: CMS Open Payments

Celerion Tempe

Neither a doctor nor a teaching hospital

Research payments

$29,866,421

20 payments

Through program year 2025, Celerion Tempe is reported as receiving $29,866,421 in research payments, across 20 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$7,488,153	6
2024	Research	$5,162,325	3
2023	Research	$10,344,611	4
2022	Research	$4,972,067	5
2021	Research	$1,899,265	2

Breakdown

Who paid Research payments · program years 2021–2025

Vertex Pharmaceuticals Incorporated $29,866,421 20 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-634 $6,423,495 2 payments
A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-668 $5,356,084 1 payment
A Phase 1, Open-label, Randomized, Parallel Study to Evaluate the Relative Bioavailability of a Tablet Formulation of VX-828 in Healthy Adult Subjects $3,788,045 1 payment
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of VX-708 in Healthy Subjects $3,104,588 2 payments
A Phase 1, Open-label Study to Evaluate the Effect of Suzetrigine on the Pharmacokinetics of Oral Contraceptives in Healthy Female Subjects $2,957,175 1 payment
VX23-548-017 rBA study for chronic pain $2,931,278 2 payments
A Phase 1, Randomized, Open-Label 2-part Study to Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor in Combination With Tezacaftor and Deutivacaftor in Healthy Adult Subjects $2,242,273 2 payments
Confirmatory BA & Food Effect $1,385,500 2 payments
A Phase 1, Open-label, Randomized, 2-part Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations in Healthy Subjects $695,756 1 payment
A Phase 1 Open-label study Evaluating the Liver Tissue Concentration of VX-864 in Subject Who Have the PiZZ Genotype Subjects $595,855 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.